
FDA Approves Kresladi: First Gene Therapy for Severe LAD-I Breakthrough
The FDA's approval of Kresladi marks a historic milestone in gene therapy, offering hope for patients with severe Leukocyte Adhesion Deficiency Type I.
Daily AI-curated articles on clinical trials, FDA updates, and pharmaceutical insights.

FDA alerts clinical researchers to Erbe flexible cryoprobe recall due to rupture risks causing hearing loss, tinnitus, and burns during ENT procedures.

Dallas cardiovascular trial tests investigational drug targeting LPA gene to reduce Lp(a) production in high-risk patients, offering new therapeutic pathway.

New 100% tariffs on imported patented drugs could reshape pharmaceutical supply chains and clinical trial operations, with significant exceptions creating complexity.

The FDA's approval of Foundayo (orforglipron) marks the fifth success under the National Priority Voucher pilot program, potentially accelerating future diabetes treatments.

FDA alerts clinical professionals about differential pressure sensor malfunctions in Abiomed Impella RP devices, prompting updated usage instructions for safer patient care.

New cardiovascular research study in Covina, CA seeks participants with established heart disease diagnosis. Study design allows continuation of existing treatments.

UK's NICE approves Wegovy for cardiovascular protection beyond weight loss, marking significant expansion in semaglutide's therapeutic applications for clinical research.

FDA approves tividenofusp alfa-eknm (Avlayah) for neurologic manifestations of Hunter syndrome, marking a significant milestone in MPS II treatment.